Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inhibikase Therapeutics Inc (IKT)

Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 135,315
  • Shares Outstanding, K 75,175
  • Annual Sales, $ 0 K
  • Annual Income, $ -48,260 K
  • EBIT $ -52 M
  • EBITDA $ -52 M
  • 60-Month Beta 0.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.10
  • Number of Estimates 1
  • High Estimate $-0.10
  • Low Estimate $-0.10
  • Prior Year $-0.15
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5700 +14.65%
on 03/30/26
2.0800 -13.46%
on 03/04/26
-0.1300 (-6.74%)
since 03/02/26
3-Month
1.4900 +20.81%
on 02/02/26
2.2600 -20.35%
on 02/25/26
-0.1500 (-7.69%)
since 01/02/26
52-Week
1.3300 +35.34%
on 11/03/25
2.3650 -23.89%
on 05/02/25
-0.3800 (-17.43%)
since 04/02/25

Most Recent Stories

More News
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options...

IKT : 1.8000 (-0.55%)
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to...

IKT : 1.8000 (-0.55%)
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to...

IKT : 1.8000 (-0.55%)
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics...

IKT : 1.8000 (-0.55%)
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE)...

IKT : 1.8000 (-0.55%)
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics...

IKT : 1.8000 (-0.55%)
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics...

IKT : 1.8000 (-0.55%)
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics...

IKT : 1.8000 (-0.55%)
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

IKT : 1.8000 (-0.55%)
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

IKT : 1.8000 (-0.55%)

Business Summary

Inhibikase Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing therapeutics for Parkinson's disease and related disorders. The company operates principally in Boston, Massachusetts. Inhibikase Therapeutics Inc. is headquartered in Atlanta, Georgia.

See More

Key Turning Points

3rd Resistance Point 1.9433
2nd Resistance Point 1.8867
1st Resistance Point 1.8433
Last Price 1.8000
1st Support Level 1.7433
2nd Support Level 1.6867
3rd Support Level 1.6433

See More

52-Week High 2.3650
Fibonacci 61.8% 1.9696
Fibonacci 50% 1.8475
Last Price 1.8000
Fibonacci 38.2% 1.7254
52-Week Low 1.3300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.